Cyclacel Pharmaceuticals (CYCC) Q2 slips on a per share basis as losses come in higher than anticipated.
Q2 EPS of ($0.10), versus ($0.45) reported last year.
Total revenue of $264K compared to $26K in prior year.
R&D expenses were $2.6M compared to $1.7M for the same period in 2012, primarily due to clinical trial and manufacturing costs.
Cash and cash equivalents totaled $33.7M.
Shares -4.4% AH.